CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer

Maura L. Gillison; George Blumenschein; Jerome Fayette; Joel Guigay; A. Dimitrios Colevas; Lisa Licitra; Kevin J. Harrington; Stefan Kasper; Everett E. Vokes; Caroline Even; Francis Worden; Nabil F. Saba; Lara Carmen Iglesias Docampo; Robert Haddad; Tamara Rordorf; Naomi Kiyota; Makoto Tahara; Manish Monga; Mark Lynch; Li Li; Robert L. Ferris

doi:10.1634/theoncologist.2017-0674

CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer

Maura L. Gillison, George Blumenschein, Jerome Fayette, Joel Guigay, A. Dimitrios Colevas, Lisa Licitra, Kevin J. Harrington, Stefan Kasper, Everett E. Vokes, Caroline Even, Francis Worden, Nabil F. Saba, Lara Carmen Iglesias Docampo, Robert Haddad, Tamara Rordorf, Naomi Kiyota, Makoto Tahara, Manish Monga, Mark Lynch, Li LiRobert L. Ferris

Thoracic Head & Neck Medical Oncology

Research output: Contribution to journal › Article › peer-review

67 Scopus citations

Abstract

Nivolumab significantly improved overall survival (OS) vs investigator's choice (IC) of chemotherapy at the primary analysis of randomized, open-label, phase 3 CheckMate 141 in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN). Here, we report that OS benefit with nivolumab was maintained at a minimum follow-up of 11.4 months. Further, OS benefit with nivolumab vs IC was also noted among patients who received first-line treatment for R/M SCCHN after progressing on platinum therapy for locally advanced disease in the adjuvant or primary (i.e., with radiation) setting.

Original language	English (US)
Pages (from-to)	1079-1082
Number of pages	4
Journal	Oncologist
Volume	23
Issue number	9
DOIs	https://doi.org/10.1634/theoncologist.2017-0674
State	Published - Sep 2018

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1634/theoncologist.2017-0674

Cite this

Gillison, M. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Harrington, K. J., Kasper, S., Vokes, E. E., Even, C., Worden, F., Saba, N. F., Iglesias Docampo, L. C., Haddad, R., Rordorf, T., Kiyota, N., Tahara, M., Monga, M., Lynch, M., ... Ferris, R. L. (2018). CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer. Oncologist, 23(9), 1079-1082. https://doi.org/10.1634/theoncologist.2017-0674

Gillison, ML , Blumenschein, G, Fayette, J, Guigay, J, Colevas, AD, Licitra, L, Harrington, KJ, Kasper, S, Vokes, EE, Even, C, Worden, F, Saba, NF, Iglesias Docampo, LC, Haddad, R, Rordorf, T, Kiyota, N, Tahara, M, Monga, M, Lynch, M, Li, L & Ferris, RL 2018, 'CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer', Oncologist, vol. 23, no. 9, pp. 1079-1082. https://doi.org/10.1634/theoncologist.2017-0674

@article{f631c936147545e98bd4a1c8a5cecbc2,

title = "CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer",

abstract = "Nivolumab significantly improved overall survival (OS) vs investigator's choice (IC) of chemotherapy at the primary analysis of randomized, open-label, phase 3 CheckMate 141 in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN). Here, we report that OS benefit with nivolumab was maintained at a minimum follow-up of 11.4 months. Further, OS benefit with nivolumab vs IC was also noted among patients who received first-line treatment for R/M SCCHN after progressing on platinum therapy for locally advanced disease in the adjuvant or primary (i.e., with radiation) setting.",

author = "Gillison, {Maura L.} and George Blumenschein and Jerome Fayette and Joel Guigay and Colevas, {A. Dimitrios} and Lisa Licitra and Harrington, {Kevin J.} and Stefan Kasper and Vokes, {Everett E.} and Caroline Even and Francis Worden and Saba, {Nabil F.} and {Iglesias Docampo}, {Lara Carmen} and Robert Haddad and Tamara Rordorf and Naomi Kiyota and Makoto Tahara and Manish Monga and Mark Lynch and Li Li and Ferris, {Robert L.}",

note = "Publisher Copyright: {\textcopyright} AlphaMed Press 2018",

year = "2018",

month = sep,

doi = "10.1634/theoncologist.2017-0674",

language = "English (US)",

volume = "23",

pages = "1079--1082",

journal = "Oncologist",

issn = "1083-7159",

publisher = "AlphaMed Press",

number = "9",

}

TY - JOUR

T1 - CheckMate 141

T2 - 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer

AU - Gillison, Maura L.

AU - Blumenschein, George

AU - Fayette, Jerome

AU - Guigay, Joel

AU - Colevas, A. Dimitrios

AU - Licitra, Lisa

AU - Harrington, Kevin J.

AU - Kasper, Stefan

AU - Vokes, Everett E.

AU - Even, Caroline

AU - Worden, Francis

AU - Saba, Nabil F.

AU - Iglesias Docampo, Lara Carmen

AU - Haddad, Robert

AU - Rordorf, Tamara

AU - Kiyota, Naomi

AU - Tahara, Makoto

AU - Monga, Manish

AU - Lynch, Mark

AU - Li, Li

AU - Ferris, Robert L.

PY - 2018/9

Y1 - 2018/9

N2 - Nivolumab significantly improved overall survival (OS) vs investigator's choice (IC) of chemotherapy at the primary analysis of randomized, open-label, phase 3 CheckMate 141 in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN). Here, we report that OS benefit with nivolumab was maintained at a minimum follow-up of 11.4 months. Further, OS benefit with nivolumab vs IC was also noted among patients who received first-line treatment for R/M SCCHN after progressing on platinum therapy for locally advanced disease in the adjuvant or primary (i.e., with radiation) setting.

AB - Nivolumab significantly improved overall survival (OS) vs investigator's choice (IC) of chemotherapy at the primary analysis of randomized, open-label, phase 3 CheckMate 141 in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN). Here, we report that OS benefit with nivolumab was maintained at a minimum follow-up of 11.4 months. Further, OS benefit with nivolumab vs IC was also noted among patients who received first-line treatment for R/M SCCHN after progressing on platinum therapy for locally advanced disease in the adjuvant or primary (i.e., with radiation) setting.

UR - http://www.scopus.com/inward/record.url?scp=85053050902&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053050902&partnerID=8YFLogxK

U2 - 10.1634/theoncologist.2017-0674

DO - 10.1634/theoncologist.2017-0674

M3 - Article

C2 - 29866947

AN - SCOPUS:85053050902

SN - 1083-7159

VL - 23

SP - 1079

EP - 1082

JO - Oncologist

JF - Oncologist

IS - 9

ER -

CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this